title: Role of lipid control in diabetic nephropathy.
abstract: Patients with diabetic nephropathy are known to be associated with many lipoprotein abnormalities, including higher plasma levels of very low-density lipoprotein, low-density lipoprotein and triglycerides, and lower levels of high-density lipoprotein. Many studies have reported that lipids may induce both glomerular and tubulointerstitial injury through mediators such as cytokines, reactive oxygen species, chemokines, and through hemodynamic changes. Clinical studies in patients with diabetic nephropathy showed that lipid control can be associated with an additional effect of reduction in proteinuria. Experimental studies demonstrated that lipid-lowering agents exerted a certain degree of renoprotection, through both indirect effects from lipid lowering and a direct effect on cell protection. Therefore, lipid control appears to be important in the prevention and treatment of diabetic nephropathy. Diabetic nephropathy has become the leading cause of end-stage renal failure in many countries, including Taiwan. One of the major risk factors for the development and progression of diabetic nephropathy is dyslipidemia. In this paper we will review the role of lipid in mediating renal injury and the beneficial effects of lipid control in diabetic nephropathy.
authors.affiliation: Division of Nephrology and Endocrinology, Department of Internal Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
authors.forename: Hung-Chun
authors.initials: HC
authors.lastname: Chen
authors.forename: Jinn-Yuh
authors.initials: JY
authors.lastname: Guh
authors.forename: Jer-Ming
authors.initials: JM
authors.lastname: Chang
authors.forename: Min-Chia
authors.initials: MC
authors.lastname: Hsieh
authors.forename: Shyi-Jang
authors.initials: SJ
authors.lastname: Shin
authors.forename: Yung-Hsiung
authors.initials: YH
authors.lastname: Lai
mesh_terms: D003928:Diabetic Nephropathies / Q000097:blood* / Q000150:complications*; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications* / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008055:Lipids / Q000097:blood*
chemical_list: D000960:Hypolipidemic Agents; D008055:Lipids